SEATTLE GENETICS INC's ticker is SGENXXXX and the CUSIP is 812578102. A total of 307 filers reported holding SEATTLE GENETICS INC in Q4 2018. The put-call ratio across all filers is 1.64 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $53,310,000 | +13.1% | 272,421 | -1.8% | 0.12% | +5.3% |
| Q2 2020 | $47,150,000 | +24.0% | 277,484 | -15.8% | 0.11% | +2.7% |
| Q1 2020 | $38,034,000 | +0.0% | 329,644 | -0.9% | 0.11% | +22.0% |
| Q4 2019 | $38,016,000 | +19.0% | 332,718 | -20.8% | 0.09% | +11.0% |
| Q3 2019 | $31,933,000 | +12.7% | 420,155 | -0.2% | 0.08% | -15.5% |
| Q2 2019 | $28,341,000 | -4.1% | 421,121 | +2.3% | 0.10% | -11.0% |
| Q1 2019 | $29,560,000 | +26.9% | 411,583 | +0.1% | 0.11% | +12.4% |
| Q4 2018 | $23,299,000 | -56.8% | 411,211 | -41.2% | 0.10% | -49.5% |
| Q3 2018 | $53,970,000 | -19.2% | 699,814 | -30.4% | 0.19% | +68.4% |
| Q2 2018 | $66,766,000 | +21.0% | 1,005,658 | -4.6% | 0.11% | +16.3% |
| Q1 2018 | $55,176,000 | +2.1% | 1,054,182 | +4.3% | 0.10% | +4.3% |
| Q4 2017 | $54,051,000 | -1.1% | 1,010,308 | +0.6% | 0.09% | -6.9% |
| Q3 2017 | $54,629,000 | +4.2% | 1,004,031 | -0.9% | 0.10% | 0.0% |
| Q2 2017 | $52,427,000 | -18.9% | 1,013,287 | -1.4% | 0.10% | -21.7% |
| Q1 2017 | $64,612,000 | +16.9% | 1,027,865 | -1.9% | 0.13% | +11.2% |
| Q4 2016 | $55,277,000 | +17.0% | 1,047,516 | +19.7% | 0.12% | +18.4% |
| Q3 2016 | $47,261,000 | +31.6% | 875,039 | -1.5% | 0.10% | +24.1% |
| Q2 2016 | $35,901,000 | +13.2% | 888,429 | -1.7% | 0.08% | +11.3% |
| Q1 2016 | $31,716,000 | -13.6% | 903,839 | +10.5% | 0.07% | -15.5% |
| Q4 2015 | $36,714,000 | +14.7% | 818,050 | -1.5% | 0.08% | +7.7% |
| Q3 2015 | $32,012,000 | -12.2% | 830,190 | +10.2% | 0.08% | -7.1% |
| Q2 2015 | $36,448,000 | +30.9% | 753,050 | -4.4% | 0.08% | +29.2% |
| Q1 2015 | $27,836,000 | +7.0% | 787,430 | -2.7% | 0.06% | +4.8% |
| Q4 2014 | $26,013,000 | -15.4% | 809,610 | -2.1% | 0.06% | -17.3% |
| Q3 2014 | $30,759,000 | -0.5% | 827,300 | +2.3% | 0.08% | +5.6% |
| Q2 2014 | $30,929,000 | -20.6% | 808,600 | -5.4% | 0.07% | -25.3% |
| Q1 2014 | $38,942,000 | +13.3% | 854,740 | -0.8% | 0.10% | +11.8% |
| Q4 2013 | $34,383,000 | -8.7% | 861,940 | +0.3% | 0.08% | -15.0% |
| Q3 2013 | $37,650,000 | +118.9% | 859,010 | +57.1% | 0.10% | +108.3% |
| Q2 2013 | $17,198,000 | – | 546,660 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Baker Brothers Advisors | 51,049,760 | $3,738,884,000 | 23.93% |
| Lagoda Investment Management, L.P. | 76,873 | $5,630,000 | 7.16% |
| Matrix Capital Management Company, LP | 3,141,852 | $230,109,000 | 6.14% |
| DOMINI IMPACT INVESTMENTS LLC | 3,120 | $229,000 | 3.51% |
| Opus Point Partners Management, LLC | 17,832 | $1,306,000 | 1.77% |
| Capital International Sarl | 188,200 | $13,784,000 | 1.72% |
| EMORY UNIVERSITY | 33,368 | $2,444,000 | 1.72% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 60,900 | $4,460,000 | 1.65% |
| CAPITAL GUARDIAN TRUST CO | 1,358,254 | $99,415,000 | 1.32% |
| Rhenman & Partners Asset Management AB | 150,598 | $11,030,000 | 1.29% |